Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-15 (canceled)

Claim 16. (currently amended): A method for the administration of therapeutic amount of a growth factor protein formulation in the treatment of a patient displaying the symptoms of acute coronary artery disease comprising the ~~step~~ steps of:

a) ~~-~~administering at least one dose of an effective amount of a first therapeutic growth factor ~~delivering the~~ protein formulation comprising a growth factor protein selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof by inhalation therapy;

b) monitoring one or more clinical indicators of acute coronary artery disease;

c) determining, based on monitoring the one or more clinical indicators of acute coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is necessary;

d) depending on the results of step c), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF1, FGF-2, VEGF, and mixtures thereof; and

e) repeating steps b) through d) until there is a clinical indication of amelioration of the symptoms of acute coronary artery disease in the patient, or until there is a contraindication to continued treatment.

Claim 17. (canceled)

Claim 18. (canceled)

Claim 19. (canceled)

Claim 20. (previously presented): The method of claim 16 wherein the growth factor protein formulation is a dry powder formulation.

Claim 21. (previously presented): The method of claim 16 wherein the growth factor protein formulation is a liquid aerosol formulation

Claim 22. (currently amended): The method of claim 16, wherein the ~~acute~~ symptoms of acute coronary artery disease are brought on by reperfusion injury.

Claim 23. (previously presented): The method of claim 22, wherein the reperfusion injury is induced by a procedure selected from the group consisting of thrombolytic therapy, bypass surgery and angioplasty.

Claim 24. (currently amended): A method for the administration of therapeutic amount of a growth factor protein formulation ~~selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof,~~ in the treatment of a patient displaying the symptoms of chronic coronary artery disease comprising the ~~step~~ steps of:

a) administering at least one dose of an effective amount of a first therapeutic growth factor ~~delivering the~~ protein formulation comprising a growth factor protein selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof by inhalation therapy;

b) monitoring one or more clinical indicators of chronic coronary artery disease;

c) determining, based on monitoring the one or more clinical indicators of chronic coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is necessary;

d) depending on the results of step c), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF1, FGF-2, VEGF, and mixtures thereof; and

e) repeating steps b) through d) until there is a clinical indication of amelioration of the symptoms of chronic coronary artery disease in the patient, or until there is a contraindication to continued treatment.

Claim 25. (canceled)

Claim 26. (canceled)

Claim 27. (previously presented): The method of claim 24 wherein the growth factor protein formulation is a dry powder formulation.

Claim 28. (previously presented): The method of claim 24 wherein the growth factor protein formulation is a liquid aerosol formulation.

Claim 29. (canceled)

Claim 30. (canceled)